Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Report Overview
Studies reveal that 9.5% of the global population is affected by liver fibrosis, with males having a higher prevalence of getting affected than females. The prevalence in males is around 10.6% while 5.4% of females may develop the condition once in a lifetime. Moreover, the prevalence increases with age. Therefore, there is a significant emphasis on developing quality medications that help in disease management effectively.
- Major companies involved in the liver fibrosis pipeline drugs market include Gilead Sciences, Intercept Pharmaceuticals and Bristol-Myers Squibb (BMS).
- Leading drugs currently under pipeline include tirzepatide, and ALG-055009 among others.
- Regulatory authorities such as the United States FDA and EMA play an essential role in the drug pipeline for liver fibrosis as they are offering breakthrough designations to manage the condition.
Report Coverage
The Liver Fibrosis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into liver fibrosis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Liver fibrosis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The liver fibrosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from liver fibrosis.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to liver fibrosis.
Liver Fibrosis Drug Pipeline Outlook
Liver fibrosis involves the formation of scar tissues in large amounts, formed as a response to repairing and replacing damaged liver cells. There are different levels of liver fibrosis which are primarily based on the degree of liver damage. The condition does not have many symptoms in the mild to moderate stages. As the patient progresses, they may encounter symptoms like appetite loss, difficulty thinking clearly, fluid buildup in the legs or stomach, jaundice (where the skin and eyes appear yellow nausea, unexplained weight loss or weakness.
Nonalcoholic fatty liver disease (NAFLD) is the most common category of liver fibrosis, followed by alcoholic liver disease, which is due to long-term excesses of drinking alcohol. The treatment varies based on the cause of illness and the symptoms of the patient. Some of the specific treatment alternatives include ACE inhibitors, direct-action antivirals, PPAR-alpha agonists and antifibrotics. Several universities and pharmaceutical companies are collaborating to develop high-efficacy drugs that manage the condition effectively. In March 2024, the United States FDA granted approval to Rezdiffra (resmetirom) for treating adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis). Such approvals indicate a promising landscape for the drugs in the disease pipeline.
Liver Fibrosis – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of liver fibrosis drugs based on several segmentations including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonists
- ACE Inhibitors
- Hepatotropic Drugs
- Others
By Route of Administration
- Oral
- Parenteral
- Others
Liver Fibrosis – Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for liver fibrosis. There are around 334 drugs in phase II of liver fibrosis drugs.
Liver Fibrosis – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under liver fibrosis pipeline analysis include peroxisome proliferator-activated receptors (PPAR)-alpha agonists, ACE inhibitors, hepatotropic drugs and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for liver fibrosis.
Liver Fibrosis Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the liver fibrosis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Liver fibrosis clinical trials:
- Eli Lilly and Company
- Gilead Sciences
- Intercept Pharmaceuticals
- Galectin Therapeutics
- Genfit
- Madrigal Pharmaceuticals
- Bristol-Myers Squibb (BMS)
- Novo Nordisk
Liver Fibrosis – Emerging Drugs Profile
Major drugs currently in the drug pipeline are as follows:
Tirzepatide
Previously approved for treating type 2 diabetes, Eli Lilly's metabolic disorder medication tirzepatide, currently under phase 2 clinical trial of a 52-week study demonstrated high efficacy against nonalcoholic steatohepatitis (NASH) with no worsening of the liver fibrosis.
ALG-055009
Aligos Therapeutics is conducting a Phase 2a study to investigate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin capsule) for 12 weeks. The study enrols 100 patients and is expected to be completed by December 2024.
Reasons To Buy This Report
The Liver Fibrosis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for liver fibrosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within liver fibrosis pipeline insights.
Key Questions Answered in the Liver Fibrosis – Pipeline Insight Report
- What is the current landscape of liver fibrosis pipeline drugs?
- How many companies are developing liver fibrosis drugs?
- How many phase III and phase IV drugs are currently present in liver fibrosis pipeline drugs?
- Which companies/institutions are leading the liver fibrosis drug development?
- What is the efficacy and safety profile of liver fibrosis pipeline drugs?
- What are the opportunities and challenges present in the liver fibrosis drug pipeline landscape?
- Which company is conducting major trials for liver fibrosis drugs?
- What geographies are covered for liver fibrosis clinical trials?
- What are emerging trends in liver fibrosis clinical trials?
Related Reports
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Purchase Full Report
Datasheet
USD 1,999
tax inclusive*
- Selected Sections, One User
- Printing Not Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Single User License
One User
USD 2,499
tax inclusive*
- All Sections, One User
- One Print Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
Five Users
USD 3,499
tax inclusive*
- All Sections, Five Users
- Five Prints Allowed
- Email Delivery in PDF
- Free Limited Customisation
- Post Sales Analyst Support
50% Discount on Next Update
Corporate License
Unlimited Users
USD 4,499
tax inclusive*
- All Sections, Unlimited Users
- Unlimited Prints Allowed
- Email Delivery in PDF + Excel
- Free Limited Customisation
- Post Sales Analyst Support
- 50% Discount on Next Update
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Our Offices
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124